Imatinib-Induced Interstitial Pneumonitis—A Literature Review and Case Report
Abstract
:Introduction
Case Report
Discussions
Highlights
Conclusions
Funding
Informed Consent Statement
Conflicts of Interest
Abbreviations
References
- Rosti, G.; Castagnetti, F.; Gugliott, G.; Baccarani, M. Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: Which, When, for Whom? Nat Rev Clin Oncol. 2016, 14, 141–154. [Google Scholar] [CrossRef]
- Gotlib, J. World Health Organization-Defined Eosinophilic Disorders: 2017 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2017, 92, 1243–1259. [Google Scholar] [CrossRef] [PubMed]
- Mughal, T.I.; Schrieber, A. Principal Long-Term Adverse Effects of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase. Biologics. 2010, 4, 315–323. [Google Scholar] [CrossRef] [PubMed]
- Watson, G.; Picardo, S.; Hodnett, P.; O’Brien, J.; Osman, N. A Rare Case of Imatinib-Induced Pneumonitis. Canc Ther & Oncol Int J. 2016, 2, 1–4. [Google Scholar]
- Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederweiser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346, 645–652. [Google Scholar] [CrossRef]
- Seddik, Y.; Sami, A.B.; Afqir, S. Interstitial Pneumonitis during Imatinib Therapy in a Patient with Gastrointestinal Stromal Tumor: A Case Report. J. Cancer Sci Ther. 2015, 7, 269–271. [Google Scholar]
- Saplontai-Pop, A.; Mot, A.; Moldovan, M.; Oprean, R.; Silaghi-Dumitrescu, R.; Orasan, O.; Parvu, M.; Gal, E.; Ionescu, C. Testing antiplatelet and antioxidant activity of the extract of seven varieties of Allium cepa L. Open Life Sci. 2015, 10, 89–98. [Google Scholar] [CrossRef]
- Rosenow, E.C., 3rd; Limper, A.H. Drug-induced pulmonary disease. Semin Respir Infect. 1995, 10, 86–95. [Google Scholar]
- Snyder, L.S.; Hertz, M.I. Cytotoxic drug-induced lung injury. Semin Respir Infect. 1988, 3, 217–228. [Google Scholar]
- Nebeker, J.R.; Barach, P.; Samore, M.H. Clarifying adverse drug events: A clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004, 140, 795–801. [Google Scholar] [CrossRef]
- Camus, P.; Fanton, A.; Bonniaud, P.; Camus, C.; Foucher, P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004, 71, 301–326. [Google Scholar] [CrossRef] [PubMed]
- Bonniaud, P.; Georges, M.; Favrolt, N.; Camus, P. Drug-induced interstitial lung diseases. Rev Prat. 2014, 64, 951–956. [Google Scholar]
- Camus, P. Interstitial lung disease from drugs, biologics, and radiation. In Interstitial Lung Disease, 5th ed.; Schwarz, M., King, T.E., Jr., Eds.; People’s Medical Publishing House: Shelton, Connectitut, USA, 2011; p. 637. [Google Scholar]
- Fujimoto, D.; Kato, R.; Morimoto, T.; Shimizu, R.; Sato, Y.; Kogo, M.; Ito, J.; Teraoka, S.; Nagata, K.; Nakagawa, A.; Ostuka, K.; Tomii, K. Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. PLoS ONE 2016, 11, 1–16. [Google Scholar] [CrossRef]
- Dhokarh, R.; Li, G.; Schmickl, C.N.; Kashyap, R.; Assudani, J.; Limper, A.H.; Gajic, O. Drug-associated acute lung injury: A population-based cohort study. Chest. 2012, 142, 845–850. [Google Scholar] [CrossRef] [PubMed]
- Goldsby, R.; Pulsipher, M.; Adams, R.; Coffin, C.; Albritton, K.; Wagner, L. Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol. 2002, 24, 694–695. [Google Scholar] [CrossRef] [PubMed]
- Ishii, Y.; Shoji, N.; Kimura, Y.; Ohyashiki, K. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Intern Med. 2006, 45, 339–340. [Google Scholar] [CrossRef]
- Breccia, M.; D’Elia, G.M.; D’Andrea, M.; Latagliata, R.; Alimena, G. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol. 2005, 74, 89–90. [Google Scholar] [CrossRef] [PubMed]
- Suceveanu, A.I.; Stoian APantea Mazilu, L.; et al. Interferon-free therapy is not a trigger for hepatocellular carcinoma in patients with chronic infection with hepatitis C Virus. Farmacia 2018, 66, 904–908. [Google Scholar] [CrossRef]
- Rosado, M.F.; Donna, E.; Ahn, Y.S. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol. 2003, 21, 3171–3173. [Google Scholar] [CrossRef]
- Wagner, U.; Staats, P.; Moll, R.; Feek, U.; Vogelmeier, C.; Groneberg, D.A. Imatinib associated pulmonary alveolar proteinosis. Am J Med. 2003, 115, 674. [Google Scholar] [CrossRef]
- Ma, C.X.; Hobday, T.J.; Jett, J.R. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003, 78, 1578–1579. [Google Scholar] [CrossRef]
- Yokoyama, T.; Miyazawa, K.; Kurakawa, E.; Nagate, A.; Shimamoto, T.; Iwaya, K.; Akata, S.; Aoshima, M.; Serizawa, H.; Ohyashiki, K. Interstitial pneumonia induced by imatinib mesylate: Pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia. 2004, 18, 645–646. [Google Scholar] [CrossRef]
- Isshiki, I.; Yamaguchi, K.; Okamoto, S. Interstitial pneumonitis during imatinib therapy. Br J Haematol. 2004, 125, 420. [Google Scholar] [CrossRef] [PubMed]
- Rajda, J.; Phatak, P.D. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Amer J Hem. 2005, 79, 80–81. [Google Scholar] [CrossRef] [PubMed]
- Grimison, P.; Goldstein, D.; Schneeweiss, J.; Murray, N. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms. Intern Med J. 2005, 35, 136–137. [Google Scholar] [CrossRef] [PubMed]
- Lin, J.T.; Yeh, K.T.; Fang, H.Y.; Chang, C.S. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma. 2006, 47, 1693–1695. [Google Scholar] [CrossRef]
- Seki, N.; Ito, A.; Watanabe, K.; Shibakuki, R.; Seto, T.; Uematsu, K.; Eguchi, K. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med. 2007, 46, 1941–1942. [Google Scholar] [CrossRef]
- Yamasawa, H.; Sugiyama, Y.; Bando, M.; Ohno, S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration. 2008, 75, 350–354. [Google Scholar] [CrossRef]
- Delomas, T.; Darne, C.; Besson, C. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leuk Lymphoma. 2012, 53, 332–333. [Google Scholar] [CrossRef]
- Lazareva, O.V.; Turkina, A.G. Drug-Induced Pneumonitis: A Rare Complication of Imatinib Mesylate Therapy in Patients with Chronic Myeloid Leukemia. In Myeloid Leukemia—Clinical Diagnosis and Treatment; Koschmieder, S., Ed.; InTech: Shanghai, China, 2012; pp. 85–94. Available online: http://www.intechopen.com/books/myeloid-leukemia-clinical-diagnosis-and-treatment/drug-induced-pneumonitis-a-rare-complication-of-imatinib-mesylate-therapy-in-patients-with-chronic-m.
- Dao, K.; Vedy, D.; Lopez, J.; Staneczek, O.; Buclin, T.; Livio, F. Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: A case report with concentration exposure data. Int J Hematol. 2013, 97, 299–300. [Google Scholar] [CrossRef]
- Eşkazan, A.E.; Salihoğlu, A.; Erturan, S.; Soysal, T. Interstitial pneumonitis in a patient with chronic myeloid leukemia. Turk J Hematol. 2013, 30, 435–436. [Google Scholar] [CrossRef]
- Go, S.W.; Kim, B.K.; Lee, S.H.; Kim, T.J.; Huh, J.Y.; Lee, J.M.; Hah, J.H.; Kim, D.W.; Cho, M.J.; Kim, T.W.; Kang, J.Y. Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis. Tuberc Respir Dis. 2013, 75, 256–259. [Google Scholar] [CrossRef] [PubMed]
- Seddik, Y.; Brahmi, S.A.; Afqir, S. Interstitial Pneumonitis during Imatinib Therapy in a Patient with Gastrointestinal Stromal Tumor: A Case Report. J Cancer Sci Ther. 2015, 7, 242–248. [Google Scholar]
- Lee, N.R.; Jang, J.W.; Kim, H.S.; Yhim, H.Y. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection. Korean J Intern Med. 2015, 30, 550–553. [Google Scholar] [CrossRef] [PubMed]
- Luo, Z.-B.; Xu, N.; Huang, X.-P.; Ouyang, G.-F. Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection. Turk J Hematol. 2017, 34, 356–381. [Google Scholar] [CrossRef] [PubMed]
- Ohnishi, K.; Sakai, F.; Kudoh, S.; Ohno, R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006, 20, 1162–1164. [Google Scholar] [CrossRef]
- Snyder, L.S.; Hertz, M.I.; Peterson, M.S.; Harmon, K.R.; Marinelli, W.A.; Henke, C.A.; Greenheck, J.R.; Chen, B.; Bitterman, P.B. Acute lung injury: Pathogenesis of intraalveolar fibrosis. J Clin Invest. 1991, 88, 663–673. [Google Scholar] [CrossRef]
- Walsh, J.; Absher, M.; Kelley, J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol. 1993, 9, 637–644. [Google Scholar] [CrossRef]
- Peerzada, M.M.; Spiro, T.P.; Daw, H.A. Pulmonary toxicities of tyrosine kinase inhibitors. Clin Adv Hematol Oncol. 2011, 9, 824–836. [Google Scholar]
- Rossi, S.E.; Erasmus, J.J.; McAdams, H.P.; Sporn, T.A.; Goodman, P.C. Pulmonary drug toxicity: Radiologic and pathologic manifestations. Radiographics 2000, 20, 1245–1259. [Google Scholar] [CrossRef]
- Seong, W.G.; Boo, K.K.; Sung, H.L.; Tae-Jung, K.; Joo, Y.H.; Jong, M.L.; Jick, H.H.; Dong, W.K.; Min, J.C.; Tae, W.K.; Ji, Y.K. Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis. Tuberc Respir Dis. 2013, 75, 256–259. [Google Scholar]
© 2020 by the author. 2020 Olga Hilda Orasan, Andreea Maria Stefan, Iulia Minciuna, Adela Sitar-Taut, George Ciulei, Simina Tarmure, Ioana Para, Flaviu Muresan, Ovidiu Fabian, Sorina Cezara Coste, Vasile Negrean, Angela Cozma, Laura Urian.
Share and Cite
Orasan, O.H.; Stefan, A.M.; Minciuna, I.; Sitar-Taut, A.; Ciulei, G.; Tarmure, S.; Para, I.; Muresan, F.; Fabian, O.; Coste, S.C.; et al. Imatinib-Induced Interstitial Pneumonitis—A Literature Review and Case Report. J. Mind Med. Sci. 2020, 7, 94-99. https://doi.org/10.22543/7674.71.P9499
Orasan OH, Stefan AM, Minciuna I, Sitar-Taut A, Ciulei G, Tarmure S, Para I, Muresan F, Fabian O, Coste SC, et al. Imatinib-Induced Interstitial Pneumonitis—A Literature Review and Case Report. Journal of Mind and Medical Sciences. 2020; 7(1):94-99. https://doi.org/10.22543/7674.71.P9499
Chicago/Turabian StyleOrasan, Olga Hilda, Andreea Maria Stefan, Iulia Minciuna, Adela Sitar-Taut, George Ciulei, Simina Tarmure, Ioana Para, Flaviu Muresan, Ovidiu Fabian, Sorina Cezara Coste, and et al. 2020. "Imatinib-Induced Interstitial Pneumonitis—A Literature Review and Case Report" Journal of Mind and Medical Sciences 7, no. 1: 94-99. https://doi.org/10.22543/7674.71.P9499
APA StyleOrasan, O. H., Stefan, A. M., Minciuna, I., Sitar-Taut, A., Ciulei, G., Tarmure, S., Para, I., Muresan, F., Fabian, O., Coste, S. C., Negrean, V., Cozma, A., & Urian, L. (2020). Imatinib-Induced Interstitial Pneumonitis—A Literature Review and Case Report. Journal of Mind and Medical Sciences, 7(1), 94-99. https://doi.org/10.22543/7674.71.P9499